Childrens Place, Inc.: Form 10-Q for the period ended Nov 1, 2014
Filed with the SEC on Dec 4, 2014 and accepted by EDGAR at Dec 4, 2014, 17:12 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2014-11-01. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2014-08-03 to 2014-11-01 | $487.3m | us-gaap:SalesRevenueNet |
| Revenue | 9 months2014-02-02 to 2014-11-01 | $1.28bn | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months2014-08-03 to 2014-11-01 | $297.2m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 9 months2014-02-02 to 2014-11-01 | $824.6m | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months2014-08-03 to 2014-11-01 | $190.1m | us-gaap:GrossProfit |
| Gross profit | 9 months2014-02-02 to 2014-11-01 | $457.5m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2014-08-03 to 2014-11-01 | $116.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2014-02-02 to 2014-11-01 | $347.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2014-08-03 to 2014-11-01 | $55.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2014-02-02 to 2014-11-01 | $59.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2014-08-03 to 2014-11-01 | $350.0k | us-gaap:InterestExpense |
| Interest expense | 9 months2014-02-02 to 2014-11-01 | $974.0k | us-gaap:InterestExpense |
| Income tax | 3 months2014-08-03 to 2014-11-01 | $18.8m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2014-02-02 to 2014-11-01 | $19.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2014-08-03 to 2014-11-01 | $36.9m | us-gaap:ProfitLoss |
| Net income | 9 months2014-02-02 to 2014-11-01 | $39.9m | us-gaap:ProfitLoss |
| Diluted EPS | 3 months2014-08-03 to 2014-11-01 | $1.70 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2014-02-02 to 2014-11-01 | $1.81 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2014-08-03 to 2014-11-01 | $1.71 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2014-02-02 to 2014-11-01 | $1.82 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2014-08-03 to 2014-11-01 | 21,756,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2014-02-02 to 2014-11-01 | 22,062,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2014-02-02 to 2014-11-01 | $68.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2014-08-03 to 2014-11-01 | $13.9m | us-gaap:PaymentsToAcquireProductiveAssets |
| Capital expenditure | 9 months2014-02-02 to 2014-11-01 | $44.6m | us-gaap:PaymentsToAcquireProductiveAssets |
| Dividends paid | 9 months2014-02-02 to 2014-11-01 | −$8.7m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months2014-02-02 to 2014-11-01 | $60.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2014-11-01 | $170.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2014-11-01 | $629.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2014-11-01 | $995.4m | us-gaap:Assets |
| Current liabilities | At period end2014-11-01 | $297.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2014-11-01 | $394.8m | us-gaap:Liabilities |
| Short-term borrowings | At period end2014-11-01 | $19.1m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2014-11-01 | $600.7m | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |
Source: SEC EDGAR, the filing index for accession 0001445305-14-005367. Last ingested by Listed: Nov 12, 2026, 18:00 ET. Listed shows no prices and gives no investment advice.